Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a histological subtype of peripheral T-cell lymphoma associated with a poor prognosis. This post-hoc pooled analysis aims to provide insight about the efficacy of pralatrexate monotherapy in a subset of twenty-nine patients with relapsed or refractory (r/r) AITL drawn from two prospective registration trials completed in China and Japan. After a median of two prior lines of therapy, an overall response rate of 52% (15/29 patients; 95% CI 0.34, 0.70) was demonstrated. The estimated median duration of response, progression free survival (PFS) and overall survival (OS) were 6.4 months (196 days), 5.0 months (151 days), and 18.0 months (548 days), respectively. Grades 1-3 mucositis was observed in twenty-three patients (79.3%); and hemato-toxicity in twenty-six (89.7%) patients. Results of this analysis corroborate with data from two previously reported US retrospective cohorts, supporting the potential benefits of pralatrexate monotherapy in patients with r/r AITL.
References
Feb 28, 2001·Leukemia Research·J LindahlE Hellström-Lindberg
Apr 9, 2004·Blood·Gunilla EnbladAnders Osterborg
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie VoseUNKNOWN International T-Cell Lymphoma Project
Dec 8, 2009·British Journal of Haematology·Laurence de LevalPhilippe Gaulard
Jan 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorSteven Horwitz
Mar 1, 2011·Blood·Richard L PiekarzSusan E Bates
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoJulie M Vose
Mar 28, 2013·Annals of Hematology·Jan-Henrik MikeschNils H Thoennissen
Jan 25, 2014·Journal of Hematology & Oncology·Bertrand CoiffierSteven Horwitz
Mar 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michinori OguraRyuzo Ueda
Mar 22, 2014·Blood·Steven M HorwitzYasuhiro Oki
Oct 31, 2014·Cancer·Ethan ToumisheyTony Reiman
Feb 18, 2015·Annals of Hematology·Yasunori KogureMineo Kurokawa
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrei Shustov
Jun 25, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y ShiX Lu
Aug 8, 2015·Annals of Hematology·Byeong-Bae ParkWon Sik Lee
Jul 16, 2016·Haematologica·Pier Luigi ZinzaniFranck Morschhauser
Dec 17, 2016·British Journal of Haematology·Dai ChiharaYasuhiro Oki
Jan 25, 2017·Blood·Matthew A Lunning, Julie M Vose
Mar 17, 2017·Journal of Hematology & Oncology·Yuankai ShiYizhuo Zhang
Aug 5, 2017·Cancer Science·Dai MaruyamaKensei Tobinai
Jul 6, 2018·Annals of Hematology·Dai MaruyamaKensei Tobinai
Mar 25, 2019·Targeted Oncology·Xiaonan HongChunxiao Cai
Jul 31, 2019·JNCI Cancer Spectrum·Owen A O'ConnorWon Seog Kim